Safety and Efficacy of Frexalimab from the Phase 2 Open-label Extension in Participants with Relapsing Multiple Sclerosis: 2-year Results (S3.006)
Report safety and efficacy of frexalimab at Week (W) 96 in the phase 2 (NCT04879628) open-label extension (OLE) in participants with relapsing multiple sclerosis (pwRMS).
Authors
- Michal Dufek (ORCID: https://orcid.org/0000-0003-3773-4510)
- Brendan Smyth (ORCID: https://orcid.org/0000-0003-1838-3348)
- Gavin Giovannoni (ORCID: https://orcid.org/0000-0001-9995-1700)
- Patrick Vermersch (ORCID: https://orcid.org/0000-0003-0997-8817)
- Yang Mao‐Draayer (ORCID: https://orcid.org/0000-0001-6248-3480)
- Xavier Montalbán (ORCID: https://orcid.org/0000-0002-0098-9918)
- Erik Wallstroem
- Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
- Philippe Truffinet (ORCID: https://orcid.org/0000-0002-5895-9981)
- Stéphane Saubadu
- Biljana Djukic
- O. I. Kalbus (ORCID: https://orcid.org/0000-0003-0796-4825)
- Xiaodong Luo (ORCID: https://orcid.org/0000-0002-8214-9874)
- Cristina Granziera (ORCID: https://orcid.org/0000-0002-4917-8761)
- Ivan Staikov
- Stephen C. Krieger (ORCID: https://orcid.org/0009-0000-8348-7923)
Institutions
- Alabama Department of Public Health (US)
- Inserm (FR)
- Queen Mary University of London (GB)
- University of Basel (CH)
- Masaryk University (CZ)
- Université de Lille (FR)
- University Hospital of Basel (CH)
- Sanofi (France) (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Oklahoma Medical Research Foundation (US)
- Acibadem City Clinic (BG)
- Sanofi (United States) (US)
- Vall d'Hebron Hospital Universitari (ES)
- St. Anne's University Hospital Brno (CZ)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208742
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00